About Serine/threonine-protein kinase 16
Serine/threonine-protein kinase 16 (STK16) is a protein
from Homo sapiens identified by UniProt accession
O75716, 305 residues long.
MolForge cross-references it against 0 known binders and
48 disease associations.
Target properties
| Protein name | Serine/threonine-protein kinase 16 |
| UniProt accession | O75716 |
| Gene | STK16 |
| Organism | Homo sapiens |
| Length | 305 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (15)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (48)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.47
- reticulocyte count · score 0.18
- reticulocyte measurement · score 0.16
- date of birth · score 0.12
- cancer · score 0.08
- triglyceride measurement · score 0.08
- lung adenocarcinoma · score 0.07
- hereditary persistence of fetal hemoglobin-sickle cell disease syndrome · score 0.06
- platelet component distribution width · score 0.06
- Red cell distribution width · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75716-F1 | alphafold | PREDICTED | 93.08 | — |
Amino-acid sequence (305 residues)
MGHALCVCSR GTVIIDNKRY LFIQKLGEGG FSYVDLVEGL HDGHFYALKR ILCHEQQDRE EAQREADMHR LFNHPNILRL VAYCLRERGA KHEAWLLLPF FKRGTLWNEI ERLKDKGNFL TEDQILWLLL GICRGLEAIH AKGYAHRDLK PTNILLGDEG QPVLMDLGSM NQACIHVEGS RQALTLQDWA AQRCTISYRA PELFSVQSHC VIDERTDVWS LGCVLYAMMF GEGPYDMVFQ KGDSVALAVQ NQLSIPQSPR HSSALRQLLN SMMTVDPHQR PHIPLLLSQL EALQPPAPGQ HTTQI
Explore Serine/threonine-protein kinase 16 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets